CYBIN INC - SECOND PHASE 3 STUDY EMBRACE EXPECTED TO BEGIN MID-2025
CYBIN - ENGAGES 18 CLINICAL SITES FOR PHASE 3 PROGRAM EVALUATING CYB003 FOR THE ADJUNCTIVE TREATMENT OF MDD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.